Latest News & Updates

Latest Articles
Rova-T Underperforms in Phase II SCLC Trial
Rovalpituzumab Tesirine (Rova-T) delivered disappointing preliminary results in the third-line setting for patients with relapsed/refractory small cell lung cancer with high DLL3 expression.
PUBLISHED: March 22, 2018
Ponatinib Maintains Benefit in Chronic-Phase CML at 5 Years
Ponatinib maintained deep, durable responses in heavily pretreated patients with chronic-phase chronic myeloid leukemia (CP-CML).
PUBLISHED: March 22, 2018
Venetoclax/Rituximab Positive PFS Data Published in NEJM
The regimen of venetoclax (Venclexta) plus rituximab (Rituxan) lowered the risk of disease progression or death by 83% versus bendamustine (Treanda) plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
PUBLISHED: March 22, 2018
FDA Approves Nilotinib for Pediatric CML
The FDA has approved nilotinib for the first- and second-line treatment of pediatric patients aged 1 year and older with Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase. 
PUBLISHED: March 22, 2018
Novel Lenvatinib Combinations Tested in Frontline RCC
The current standard-of-care therapy for patients with clear cell renal cell carcinoma is sunitinib, but many patients relapse or don't have responses to the drug.
PUBLISHED: March 22, 2018
Latest Peer Exchange Discussions
MDS: The Current Understanding in Molecular Testing and Biomarkers
Panelists James M. Foran, MD, FRCPC, and Azra Raza, MD, provide insight on the current understanding in molecular testing and biomarkers in myelodysplastic syndrome. View Now
ALK-Positive Lung Cancer
Panelists Mark A. Socinski, MD; Gregory J. Riely, MD, PhD; Jared Weiss, MD; Thomas E. Stinchcombe, MD; and Benjamin P. Levy, MD; provide insight on the treatment options in ALK-positive lung cancer. View Now
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Translating Recent Data Into Informed Sequencing Decisions in Advanced Non–Small Cell Lung CancerMar 31, 20182.0
Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 31, 20182.0
Community Practice Connections™: 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationMar 31, 20182.0
Medical Crossfire®: Bridging Emerging Data to Advance Treatment Planning for Hepatocellular Carcinoma: A Multidisciplinary Tumor BoardMar 31, 20182.0
Publication Bottom Border
Border Publication